相較於一般族群，洗腎病人存在著較高的心血管罹病率和死亡率。許多研究指出洗腎病人有著明顯的發炎狀態和較高的氧化壓力，而這兩個現象都能促使粥狀硬化的病理發展加快。有證據指出，降低發炎和氧化壓力可以改善心血管疾病的預後，而statins在非洗腎族群已知有降低發炎指標和氧化壓力的效果。由於洗腎族群常伴隨有血脂異常，因此以statins進行降血脂治療是可行的想法。而對於無糖尿病且血脂正常的洗腎病人投予statin類藥物，是否能降低其血中的發炎和氧化壓力指標呢？因為相關研究較少，仍有待進一步確認。
　　我們設計了一個開放性的隨機對照臨床試驗，以觀察fluvastatin使用於無糖尿病、血脂正常到輕度異常的洗腎病人，能否降低其發炎和氧化壓力的指標。研究共分四組，研究組分別給予每日20、40、80mg的fluvastatin，對照組則未給藥；實驗共進行8週。主要監測的指標有：hsCRP、IL-6、TNF-α、sPLA2、Protein carbonyl、MDA與Nitrotyrosine，次要指標則有血脂肪與其他例行檢測的生化指標等。
　　研究開始時共收案了個81病人，完成實驗的則有74人；四組之間的人數、人口學特性、疾病狀況、慢性病用藥等方面都無顯著差異。主要指標方面：hs-CRP、IL-6與Nitrotyrosine無顯著變化，TNF-α在80mg組顯著降低；sPLA2和Protein carbonyl在40mg與80mg兩組都有顯著降低；MDA則在合併實驗組一起分析後，可看出顯著的降低。次要指標方面：實驗組的LDL都有顯著將低；總膽固醇在給藥的三組的都有下降，但僅40mg和80mg達到顯著差別。副作用方面：除了40mg組有明顯較多的病人出現脹氣，20mg組一位病人出現無法解釋的肝功能指數升高大於三倍等情況之外，其他四組間均無顯著差別，也未出現嚴重的不良反應事件。
　　依據實驗的結果可知，在血脂正常到輕度異常的無糖尿病洗腎病人身上投予不同劑量的fluvastatin八週，無法降低IL-6、hs-CRP與NO2-Tyr；但可以降低sPLA2、TNF-α、PC，而且和劑量有關；並且可能可以降低MDA，但需要較大的樣本數才可以證明。

　　Compared to general population, hemodialysis patients have higher cardiovascular morbidity and mortality. The atherogenesis was accelerated in dialysis patients. Evidences have pointed out the prognosis of cardiovascular disease can be improved by the reducing inflammation and oxidative stress, and statins are found to be beneficial in non-dialysis patients. Administration of statins in hemodialysis (HD) patients may be a feasible idea for the dyslipidemia, which is not unusual in this population. It remains unclear if statins can reduced the inflammation and oxidative stress in non-DM patients with normal lipid profile.
　　We had designed a non-blinding randomized control trial to investigate the ability of lowering of inflammation and oxidative stress of fluvastatin in non-DM HD patients with normal blood-lipid. Study groups were assigned to administer 20, 40, and 80mg of fluvastatin per day for 8 weeks. The measurements of primary outcome were the change of hsCRP, IL-6, TNF-α, sPLA2, Protein carbonyl, MDA and Nitrotyrosine; and the secondary outcome included the changes of blood-lipids, and other indicators.
　　Eighty one patients were included and 74 completed the experiment. Patient numbers, demographic characteristics, disease state and the use of medicine for chronic disease were not significant different among the 4 groups. HsCRP, IL-6 and Nitrotyrosine have no significant changes, TNF-α was reduced evidently in 80mg group; sPLA2 and Protein carbonyl were reduced in 40mg and 80mg significantly; MDA showed significant decrease in study groups if data was analyzed collectively. LDL was reduced in all study groups significantly, and the same changes of total cholesterol only in 40mg and 80mg groups. Flatus were concentrated on 40mg group, and other side effects did not show significant different among groups. Only one patient dropped out with unexplainable elevation of liver function test.
　　On the basis of the results, we concluded that the administration of fluvastatin with different doses in non-DM HD patients with normal blood-lipid could not reduce IL-6、hsCRP and NO2-Tyr; and could reduce sPLA2, TNF-α and PC with a dose-related effects; and could reduced MDA probably in a larger sample size.

1.Rostand SG. Coronary heart disease in chronic renal insufficiency: some management considerations. J Am Soc Nephrol 2000;11(10):1948-56.

2.Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999;10(7):1606-15.

3.台灣腎臟醫學會. 92年度透析病患年度報告. 台北市; 2005.

4.行政院衛生署. 九十二年死因統計. In: 統計室, ed.; 民國92年.

5.Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356(9224):147-52.

6.Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14(9 Suppl 4):S315-20.

7.Menon V, Sarnak MJ. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis 2005;45(1):223-32.

8.Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006;83(2):456S-60S.

9.Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003;21(10):1787-803.

10.Kofler S, Nickel T, Weis M. Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci (Lond) 2005;108(3):205-13.

11.Liuba P, Pesonen E. Infection and early atherosclerosis: does the evidence support causation? Acta Paediatr 2005;94(6):643-51.

12.Haddy N, Sass C, Droesch S, et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003;170(2):277-83.

13.Kanda T, Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004;45(2):183-93.

14.Omoigui S. Cholesterol synthesis is the trigger and isoprenoid dependent interleukin-6 mediated inflammation is the common causative factor and therapeutic target for atherosclerotic vascular disease and age-related disorders including osteoporosis and type 2 diabetes. Med Hypotheses 2005;65(3):559-69.

15.Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res 2005;66(2):265-75.

16.Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3(8):1618-27.

17.Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836-43.

18.Ridker PM. C-reactive protein, inflammation, and cardiovascular disease: clinical update. Tex Heart Inst J 2005;32(3):384-6.

19.Sarzi-Puttini P, Atzeni F, Doria A, Iaccarino L, Turiel M. Tumor necrosis factor-alpha, biologic agents and cardiovascular risk. Lupus 2005;14(9):780-4.

20.Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phospholipase A(2) in vascular disease. Circ Res 2001;89(4):298-304.

21.Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 2003;14(4):347-52.

22.Sudhir K. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 2005;90(5):3100-5.

23.Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA. C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 2006;47(2):212-22.

24.Hurt-Camejo E, Camejo G, Sartipy P. Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 2000;11(5):465-71.

25.Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des 2004;10(14):1699-711.

26.Madamanchi NR, Hakim ZS, Runge MS. Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes. J Thromb Haemost 2005;3(2):254-67.

27.Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Semin Dial 2004;17(6):449-54.

28.Le NA. Inflammation, oxidative stress, and atherosclerosis. Curr Opin Lipidol 2004;15(2):227-9.

29.Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113(13):1708-14.

30.Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24(5):816-23.

31.Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16(7):831-42.

32.Stocker R, Keaney JF, Jr. New insights on oxidative stress in the artery wall. J Thromb Haemost 2005;3(8):1825-34.

33.Soccio M, Toniato E, Evangelista V, Carluccio M, De Caterina R. Oxidative stress and cardiovascular risk: the role of vascular NAD(P)H oxidase and its genetic variants. Eur J Clin Invest 2005;35(5):305-14.

34.Molavi B, Mehta JL. Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol 2004;19(5):488-93.

35.Ridnour LA, Thomas DD, Mancardi D, et al. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol Chem 2004;385(1):1-10.

36.Mancardi D, Ridnour LA, Thomas DD, et al. The chemical dynamics of NO and reactive nitrogen oxides: a practical guide. Curr Mol Med 2004;4(7):723-40.

37.Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol 2004;15(3):538-48.

38.Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of oxidative damage in human disease. Clin Chem 2006;52(4):601-23.

39.Liu X, Qin W, Yin D. Biochemical relevance between oxidative/carbonyl stress and elevated viscosity of erythrocyte suspensions. Clin Hemorheol Microcirc 2004;31(2):149-56.

40.Rittie L, Monboisse JC, Gorisse MC, Gillery P. Malondialdehyde binding to proteins dramatically alters fibroblast functions. J Cell Physiol 2002;191(2):227-36.

41.Taccone-Gallucci M, Lubrano R, Meloni C, Morosetti M, Adolfo CM, Casciani CU. Malonyldialdehyde content of cell membranes is the most important marker of oxidative stress in haemodialysis patients. Nephrol Dial Transplant 1998;13(10):2711-2.

42.Trevisan M, Browne R, Ram M, et al. Correlates of markers of oxidative status in the general population. Am J Epidemiol 2001;154(4):348-56.

43.Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care 2000;23(2):234-40.

44.Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 2004;44(4):381-6.

45.Mathur S, Devaraj S, Jialal I. Accelerated atherosclerosis, dyslipidemia, and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hypertens 2002;11(2):141-7.

46.Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003;18(7):1272-80.

47.Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003;12(6):593-8.

48.Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005;9(1):37-46.

49.Martin CJ, Goeddeke-Merickel CM. Oxidative stress in chronic kidney disease. Nephrol Nurs J 2005;32(6):683-5.

50.Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 2001;59(2):407-14.

51.Ward RA, McLeish KR. Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 2003;27(3):230-6.

52.Miyata T, van Ypersele de Strihou C, Kurokawa K, Baynes JW. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999;55(2):389-99.

53.Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997;8(3):475-86.

54.Handelman GJ. Efforts to determine the role of oxidant stress in dialysis outcomes. Semin Dial 2003;16(6):488-91.

55.Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35(3):469-76.

56.Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999;55(2):648-58.

57.Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65(3):1009-16.

58.Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. Nephrol Dial Transplant 2003;18(5):892-8.

59.Koken T, Serteser M, Kahraman A, Gokce C, Demir S. Changes in serum markers of oxidative stress with varying periods of haemodialysis. Nephrology (Carlton) 2004;9(2):77-82.

60.Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65(6):2371-9.

61.Samouilidou EC, Grapsa EJ, Kakavas I, Lagouranis A, Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int Urol Nephrol 2003;35(3):393-7.

62.Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006;47(1):139-48.

63.Dursun E, Dursun B, Suleymanlar G, Ozben T. Carbonyl stress in chronic renal failure: the effect of haemodialysis. Ann Clin Biochem 2005;42(Pt 1):64-6.

64.Lim P-S, Chen T-T, Chang Y-M, Yang S-M, Chien S-W, Pai M-AT. Elevated Plasma Protein Carbonyl Level is a Major Risk Factor for Ischemic Heart Disease in Hemodialysis Patients. Acta Nephrologica 2003;17:10-6.

65.Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001;16(2):335-40.

66.Danielski M, Ikizler TA, McMonagle E, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis 2003;42(2):286-94.

67.Khan Q, Mehta JL. Relevance of platelet-independent effects of aspirin to its salutary effect in atherosclerosis-related events. J Atheroscler Thromb 2005;12(4):185-90.

68.Hamilton CA, Miller WH, Al-Benna S, et al. Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 2004;106(3):219-34.

69.Fenster BE, Tsao PS, Rockson SG. Endothelial dysfunction: clinical strategies for treating oxidant stress. Am Heart J 2003;146(2):218-26.

70.Hornig B. Vitamins, antioxidants and endothelial function in coronary artery disease. Cardiovasc Drugs Ther 2002;16(5):401-9.

71.Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356(9237):1213-8.

72.Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003(84):S207-10.

73.Krane V, Wanner C. Statins and aspirin in chronic kidney disease: what does the UK-HARP-I trial tell us? Am J Kidney Dis 2005;45(3):607-9.

74.Baigent C, Landray M, Leaper C, et al. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005;45(3):473-84.

75.Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003;63(1):12-23.

76.Norata GD, Pirillo A, Catapano AL. Statins and oxidative stress during atherogenesis. J Cardiovasc Risk 2003;10(3):181-9.

77.Ortego M, Gomez-Hernandez A, Vidal C, et al. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J Cardiovasc Pharmacol 2005;45(5):468-75.

78.Otto A, Fontaine D, Fontaine J, Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol 2005;46(2):177-84.

79.Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002;51(2):58-62.

80.Grip O, Janciauskiene S, Lindgren S. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis 2004;10(3):193-200.

81.Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108(4):426-31.

82.Seliger SL, Stehman-Breen CO. Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dial 2003;16(3):179-85.

83.Kizu A, Shioi A, Jono S, Koyama H, Okuno Y, Nishizawa Y. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem 2004;93(5):1011-9.

84.Heusinger-Ribeiro J, Fischer B, Goppelt-Struebe M. Differential effects of simvastatin on mesangial cells. Kidney Int 2004;66(1):187-95.

85.Yasunari K, Maeda K, Minami M, Yoshikawa J. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress. Arterioscler Thromb Vasc Biol 2001;21(6):937-42.

86.Tsubouchi H, Inoguchi T, Sonta T, et al. Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 2005;39(4):444-52.

87.Delbosc S, Cristol JP, Descomps B, Mimran A, Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 2002;40(2):142-7.

88.Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003;108(17):2113-20.

89.Yamaguchi Y, Matsuno S, Kagota S, Haginaka J, Kunitomo M. Peroxynitrite-mediated oxidative modification of low-density lipoprotein by aqueous extracts of cigarette smoke and the preventive effect of fluvastatin. Atherosclerosis 2004;172(2):259-65.

90.Vecchione C, Brandes RP. Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice. Circ Res 2002;91(2):173-9.

91.Moriyama T, Kawada N, Nagatoya K, et al. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001;59(6):2095-103.

92.Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005;45(1):2-14.

93.Nishikawa O, Mune M, Miyano M, et al. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int Suppl 1999;71:S219-21.

94.Ichihara A, Hayashi M, Ryuzaki M, Handa M, Furukawa T, Saruta T. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17(8):1513-7.

95.Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002;39(6):1213-7.

96.van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol 2003;16(2):238-44.

97.Vernaglione L, Cristofano C, Muscogiuri P, Chimienti S. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? Am J Kidney Dis 2004;43(3):471-8.

98.Editors M. Micromedex. In: Thomson Healthcare; 2006.

99.Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN, Jr., Sunderman FW, Jr. Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde-thiobarbituric acid adduct. Clin Chem 1987;33(2 Pt 1):214-20.

100.Levine RL, Garland D, Oliver CN, et al. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990;186:464-78.

101.Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol 2003;14(8 Suppl 3):S254-8.

102.Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003;14(8 Suppl 3):S227-32.

103.Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003;14(8 Suppl 3):S241-5.

104.Carroll MF, Schade DS. Timing of antioxidant vitamin ingestion alters postprandial proatherogenic serum markers. Circulation 2003;108(1):24-31.

105.李金鳳. 中西醫門診病患對傳統醫療認知、情意輿行為意向之調查研究. 台北: 國立陽明大學; 1990.

106.吳建遠. 使用大陸中成藥民眾之用要認知與其醫療服務利用之相關性. 台北: 國立陽明大學; 1995.

107.張麗春. 居家癌症患者希望狀態與尋求非傳統西醫治療行為相關因素探討 台北: 國立陽明大學; 2000.

108.許金蘭. 透析患者自我醫療及影響因素之回溯性研究 台北: 國立陽明大學; 2004.

109.李珮端. 臺灣中部地區中西藥物併用之概況調查 In: 行政院衛生署, ed.: 中醫藥年報; 民國92年:413-59.

110.陳永昌, 黃正誼, 方基存, 賴彬卿, 洪振傑. 腎衰竭病患手冊. 3 ed: 長庚紀念醫院林口醫學中心腎臟科; 2005.